SCHEMBL5353608

SCHEMBL5353608

CN(C)/C=C(/C(=O)c1cccc(F)c1)c1ccncc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.50
CES1 P23141 1/20 0.50
GRM1 Q13255 1/20 0.46
KMT2A Q03164 3/20 0.45
CYP2C9 P11712 5/20 0.41
CYP3A4 P08684 4/20 0.41
CYP1A2 P05177 3/20 0.41
CYP2D6 P10635 3/20 0.41
TSHR P16473 2/20 0.41
ALDH1A1 P00352 1/20 0.41
HIF1A Q16665 1/20 0.41
PARP1 P09874 1/20 0.41
CYP2C19 P33261 4/20 0.40
HTT P42858 1/20 0.40
HDAC1 Q13547 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
PLA2G7 Q13093 1/20 0.38
MEN1 O00255 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5353609 1.00 CES2 (0.50) CES2CES1GRM1KMT2ACYP2C9
SCHEMBL1850663 0.84 MAPT (0.46) KMT2ACYP3A4CYP1A2CYP2D6TSHR
SCHEMBL1850661 0.84 MAPT (0.46) KMT2ACYP3A4CYP1A2CYP2D6TSHR
SCHEMBL4051496 0.84 CES2 (0.44) CES2CES1GRM1KMT2AALDH1A1
SCHEMBL4051492 0.84 CES2 (0.44) CES2CES1GRM1KMT2AALDH1A1
SCHEMBL1554577 0.83 CES2 (0.44) CES2CES1GRM1KMT2AHTT
SCHEMBL1554579 0.83 CES2 (0.44) CES2CES1GRM1KMT2AHTT
SCHEMBL2924907 0.83 LTA4H (0.53) CES2CES1GRM1KMT2ACYP1A2
SCHEMBL2924909 0.83 LTA4H (0.53) CES2CES1GRM1KMT2ACYP1A2
SCHEMBL1150862 0.83 LTA4H (0.53) CES2CES1GRM1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1553096-B1 PYRAZOLE COMPOUNDS UBE INDUSTRIES (JP) 2012-10-31 EP disclosed
US-7294625-B2 Pyrazole compounds UBE INDUSTRIES, LTD. (JP) 2007-11-13 US disclosed
US-20060063934-A1 3-Pyridazonyl- or triazolopyridazinyl- 4-pyridinyl- or pyrimidinyl- pyrazoles, e.g., 4-(2-aminopyridin-4-yl)-3-phenyl-1-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazole; p38MAP kinase inhibitors, used to treat rheumatoid arthritis UBE INDUSTRIES, LTD. (JP) 2006-03-23 US disclosed
EP-1553096-A1 PYRAZOLE COMPOUNDS Ube Industries, Ltd. (JP) 2005-07-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063934-A1 3-Pyridazonyl- or triazolopyridazinyl- 4-pyridinyl- or pyrimidinyl- pyrazoles, e.g., 4-(2-aminopyridin-4-yl)-3-phenyl-1-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazole; p38MAP kinase inhibitors, used to treat rheumatoid arthritis CNKSR1, MAPK1, MAPK3 CES2 4513/4885CES1 2804/4885GRM1 737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.